Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.

Experimental neurology - 1 Jul 2016

Linares Gabriel R, Chiu Chi-Tso, Scheuing Lisa, Leng Yan, Liao Hsiao-Mei, Maric Dragan, Chuang De-Maw

Abstract excerpt

Huntington's disease (HD) is a fatal neurodegenerative disorder caused by CAG repeat expansions in the huntingtin gene. Although, stem cell-based therapy has emerged as a potential treatment for neurodegenerative diseases, limitations remain, including optimizing delivery to the brain and donor cell loss after transplantation. One strategy to boost cell survival and efficacy is to precondition cells before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimanic Agents
Share to Dopamine and cAMP-Regulated Phosphoprotein 32

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntingtin Protein

Share to Lithium Chloride

Share to Mesenchymal Stem Cell Transplantation

Share to Phosphopyruvate Hydratase

Share to Receptors, Cytokine

Share to Valproic Acid

Source

Identifiers

PMID: 27085395
DOI: 10.1016/j.expneurol.2016.04.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.PMID 27085395Read ↗

Mesenchymal Stem Cell-based Therapies Applied in Neurological DiseasesSemantic proximity Read ↗

Advances in Stem Cell Therapy for Huntington’s Disease: A Comprehensive Literature ReviewSemantic proximity Read ↗

Human Neural Stem Cells Differentiate and Integrate, Innervating Implanted zQ175 Huntington’s Disease Mouse StriatumSemantic proximity Read ↗

Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.Semantic proximity Read ↗

Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington's disease mice and innervate the striatum.Semantic proximity Read ↗

Transplants of Adult Mesenchymal and Neural Stem Cells Provide Neuroprotection and Behavioral Sparing in a Transgenic Rat Model of Huntington’s DiseaseSemantic proximity Read ↗

Therapeutic advances in neural regeneration for Huntington's diseaseSemantic proximity Read ↗

Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease MiceSemantic proximity Read ↗

Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.Semantic proximity Read ↗

Use of human stem cells in Huntington disease modeling and translational research.Semantic proximity Read ↗

Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington’s disease phenotypes in R6/2 miceSemantic proximity Read ↗

Stem cell therapy for central nervous system disorders: Metabolic interactions between transplanted cells and local microenvironmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.